EUCTR2013-005456-15-ES进行中（未招募）不适用
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients with Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up. Informed consent must be obtained prior to start of the screening process. Procedures conducted as part of the patient?s routine clinical management (e.g. blood count, imaging tests, etc.) and obtained prior to signature of informed consent may be used for screening or baseline purposes as long as these procedures are conducted as specified in the protocol.
- •2.Age ? 18 years or legal age of consent if greater than 18 years.
- •3.Histologic diagnosis of solitary fibrous tumor (stratum 1) or extraskeletal myxoid chondrosarcoma (stratum 2) (unresectable, locally advanced or metastatic disease) confirmed by central pathology review. Paraffin-embedded tumor tissue must be provided for all subjects for biomarker analysis before and (when feasible) after treatment with investigational product.
- •4.Patients with metastatic tumor suitable for complete resection can be recruited. In absence of progressive disease these patients should be treated with the study drug for at least 6 months.
- •5.For patients who have received previous anticancer treatments, progressive disease must be demonstrated within 6 months prior to enrollment.
- •6.Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- •7.Measurable disease according to Choi (SFT) and RECIST 1.1 (EMC) criteria. Patients must have at least one measurable lesion (not in a previously irradiated area). If the only measurable disease is in a previously irradiated area, documented progression should exist after radiotherapy within the 6 months prior to enrollment.
- •8.Patients could have received a maximum of 4 lines of chemotherapy for metastatic disease prior to trial enrollment.
- •9.Patients must be able to swallow and retain the study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Prior malignancy, except patients who have had another malignancy and have been disease-free for 10 years, or those with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma.
- •2.Central nervous system metastases at baseline, with the exception of patients who have previously-treated central nervous system metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants in prior 6-month time interval.
- •3.Patients who have received previous antiangiogenic agents.
- •4.Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:
- •?Active peptic ulcer disease
- •?Known intraluminal metastatic lesion(s) with risk of bleeding
- •?Inflammatory bowel disease (e.g. ulcerative colitis, Chrohn?s disease), or other gastrointestinal conditions with increased risk of perforation
- •?History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment
- •5.Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:
- •?Malabsorption syndrome
- •?Major resection of the stomach or small bowel
- •6.Corrected QT interval (QTc) > 480 msecs.
- •7.History of any one or more of the following cardiovascular conditions within the past 6 months:
- •?Cardiac angioplasty or stenting
- •?Myocardial infarction
- •?Unstable angina
- •?Coronary artery bypass graft surgery
- •?Symptomatic peripheral vascular disease
- •?Class II, III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
研究者
相似试验
进行中（未招募）
1 期
A phase II trial of pazopanib drug given to patients with solitary fibrous tumor (SFT) and extraskeletal myxoid chondrosarcoma (EMC) that cannot be removed with surgery or having metastasisPatients with unresectable, locally advanced or metastatic solitary fibrous tumor (SFT) or extraskeletal myxoid chondrosarcoma (EMC)EUCTR2013-005456-15-ITGrupo Español de Investigación en Sarcomas70
进行中（未招募）
不适用
Study of the efficacy of pazopanib drug given to patients with solitary fibrous tumor (SFT) and extraskeletal myxoid chondrosarcoma (EMC) that cannot be removed with surgery or having metastasisPatients with unresectable, locally advanced or metastatic solitary fibrous tumor (SFT) or extraskeletal myxoid chondrosarcoma (EMC).MedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-005456-15-FRGrupo Español de Investigación en Sarcomas70
进行中（未招募）
1 期
A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER] - PANTHER (version 6, 23 March 2012)EUCTR2009-016675-29-GBQueen Mary university of London104
已完成
2 期
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid ChondrosarcomaExtraskeletal Myxoid ChondrosarcomaSolitary Fibrous TumorNCT02066285Grupo Espanol de Investigacion en Sarcomas96
已完成
2 期
Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcomarelapsed or metastatic soft tissue sarcomaC49Malignant neoplasm of other connective and soft tissueDRKS00003139niversitätsklinikum Halle (Saale)90